In the present study, we retrospectively evaluated the clinical significance of the CTS5 score in predicting the risk of late DR, after 5-year adjuvant endocrine therapy without any recurrences, in postmenopausal women with ER+ early breast cancer who were treated in our own department. This evidence concerns the gene ESR1 and breast carcinoma.